Summit Therapeutics Stock Forecast, Price & News

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Summit Therapeutics in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Summit Therapeutics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SMMT, but not buy additional shares or sell existing shares.
View analyst ratings for Summit Therapeutics or view top-rated stocks.

Wall Street analysts have given Summit Therapeutics a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Summit Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Summit Therapeutics saw a decline in short interest during the month of August. As of August 13th, there was short interest totaling 688,600 shares, a decline of 18.6% from the July 29th total of 845,900 shares. Based on an average daily volume of 219,100 shares, the days-to-cover ratio is presently 3.1 days. Currently, 2.8% of the shares of the stock are sold short.
View Summit Therapeutics' Short Interest.

Summit Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, November 15th 2021.
View our earnings forecast for Summit Therapeutics.

Summit Therapeutics Inc. (NASDAQ:SMMT) released its earnings results on Wednesday, August, 11th. The company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.18) by $0.09. Summit Therapeutics had a negative net margin of 350.72% and a negative trailing twelve-month return on equity of 96.34%.
View Summit Therapeutics' earnings history.

Summit Therapeutics' stock was trading at $1.89 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, SMMT shares have increased by 242.9% and is now trading at $6.48.
View which stocks have been most impacted by COVID-19.

Some companies that are related to Summit Therapeutics include ATA (ATAI), Verve Therapeutics (VERV), Taro Pharmaceutical Industries (TARO), IGM Biosciences (IGMS), Atea Pharmaceuticals (AVIR), Corcept Therapeutics (CORT), Ligand Pharmaceuticals (LGND), Morphic (MORF), Harmony Biosciences (HRMY), Organogenesis (ORGO), Cassava Sciences (SAVA), Rocket Pharmaceuticals (RCKT), Ironwood Pharmaceuticals (IRWD), Nuvation Bio (NUVB) and Indivior (INVVY).
View all of SMMT's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Summit Therapeutics investors own include Energy Transfer (ET), Summit Therapeutics (SUMM), Sarepta Therapeutics (SRPT), (CATB), Gilead Sciences (GILD), CBL & Associates Properties (CBL), SandRidge Permian Trust (PER), Cornerstone Total Return Fund (CRF), Ford Motor (F) and Martin Midstream Partners (MMLP).

(SMMT) raised $40 million in an IPO on Thursday, March 5th 2015. The company issued 3,500,000 shares at a price of $11.54 per share. JMP Securities and Oppenheimer & Co. acted as the underwriters for the IPO and Needham was co-manager.

Summit Therapeutics trades on the NASDAQ under the ticker symbol "SMMT."

Summit Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (1.13%), Vanguard Group Inc. (0.90%), Baillie Gifford & Co. (0.45%), State Street Corp (0.26%), Geode Capital Management LLC (0.23%) and Morgan Stanley (0.22%). Company insiders that own Summit Therapeutics stock include David Jonathan Powell, Maky Zanganeh and Robert W Duggan.
View institutional ownership trends for Summit Therapeutics.

SMMT stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Bank of America Corp DE, Citigroup Inc., and JPMorgan Chase & Co..
View insider buying and selling activity for Summit Therapeutics or view top insider-selling stocks.

SMMT stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Vanguard Group Inc., State Street Corp, Geode Capital Management LLC, Baillie Gifford & Co., Renaissance Technologies LLC, Charles Schwab Investment Management Inc., and Nuveen Asset Management LLC. Company insiders that have bought Summit Therapeutics stock in the last two years include Maky Zanganeh, and Robert W Duggan.
View insider buying and selling activity for Summit Therapeutics or or view top insider-buying stocks.

Shares of SMMT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of SMMT stock can currently be purchased for approximately $6.48.

Summit Therapeutics has a market capitalization of $631.04 million and generates $20.17 million in revenue each year. The company earns $-52,700,000.00 in net income (profit) each year or ($0.75) on an earnings per share basis.

Summit Therapeutics employs 80 workers across the globe.

The official website for Summit Therapeutics is www.summitplc.com.

Summit Therapeutics is headquartered at 136a Eastern Avenue Milton Park, Abingdon X0, OX144SB.

Summit Therapeutics' mailing address is 136a Eastern Avenue Milton Park, Abingdon X0, OX144SB. The company can be reached via phone at 617-514-7149 or via email at [email protected].